+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Female Infertility Drugs Market 2019-2023 - Product Image

Global Female Infertility Drugs Market 2019-2023

  • ID: 4825167
  • Report
  • August 2019
  • Region: Global
  • 129 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Allergan Plc
  • Ferring BV
  • Merck KGaA
  • Novartis AG
  • Sanofi.
  • MORE
Global Female Infertility Drugs Market: About this market

The female infertility drugs market analysis considers sales from segments including parenteral, oral, and others. Our analysis also considers the sales of female infertility drugs in Asia, Europe, North America, and ROW. In 2018, the parenteral segment had a significant market share, and this trend is expected to continue over the forecast period. The parenteral route is more convenient for peptide drugs. This factor will play a significant role in the parenteral segment to maintain its market position. Also, our global female infertility drugs market report looks at factors such as the high prevalence of female infertility, high-risk factors for female infertility, and adverse outcomes and high cost of non-therapeutics. However, the availability of alternative treatment options, weak late-stage pipeline, and stringent regulations may hamper the growth of the female infertility drugs industry over the forecast period.

Global Female Infertility Drugs Market: Overview

Adverse outcomes and high cost of non-therapeutics

Non-therapeutics such as ART procedures, ICSI, IUI, crypto preservation of gametes and embryos, and IVF are expensive. Also, the cost burden on patients in the US is high due to lack of insurance coverage. These factors will boost the demand for female infertility drugs and lead to the expansion of the global female infertility drugs market at a CAGR of over 5% during the forecast period.

Introduction of biosimilars

Biosimilars are identical copies of original biologics, which are highly expensive. This is driving the demand for biosimilars. In addition, they are gaining traction in the market because they promote patient adherence. This factor is expected to have a positive impact on the overall market growth.

Competitive Landscape

With the presence of several major players, the global female infertility drugs market is fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading female infertility drugs manufacturers, that include Allergan Plc, Ferring BV, Merck KGaA, Novartis AG, and Sanofi.

Also, the female infertility drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Allergan Plc
  • Ferring BV
  • Merck KGaA
  • Novartis AG
  • Sanofi.
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY ROA
  • Market segmentation by RoA
  • Comparison by RoA
  • Parenteral - Market size and forecast 2018-2023
  • Oral - Market size and forecast 2018-2023
  • Others - Market size and forecast 2018-2023
  • Market opportunity by RoA
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 11: MARKET TRENDS
  • Increasing awareness about female infertility
  • Patient assistance programs
  • Introduction of biosimilars
PART 12: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
PART 13: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Allergan Plc
  • Ferring BV
  • Merck KGaA
  • Novartis AG
  • Sanofi
PART 14: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors
List of Exhibits:
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: RoA - Market share 2018-2023 (%)
Exhibit 18: Comparison by RoA
Exhibit 19: Parenteral - Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Parenteral - Year-over-year growth 2019-2023 (%)
Exhibit 21: Oral - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Oral - Year-over-year growth 2019-2023 (%)
Exhibit 23: Others - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Others - Year-over-year growth 2019-2023 (%)
Exhibit 25: Market opportunity by RoA
Exhibit 26: Customer landscape
Exhibit 27: Market share by geography 2018-2023 (%)
Exhibit 28: Geographic comparison
Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 30: Number of STD cases in US 2017
Exhibit 31: North America - Year-over-year growth 2019-2023 (%)
Exhibit 32: Top 3 countries in North America
Exhibit 33: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in Europe
Exhibit 36: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 37: Prevalence of infertility in some Indian states
Exhibit 38: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 39: Top 3 countries in Asia
Exhibit 40: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 41: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 42: Top 3 countries in ROW
Exhibit 43: Key leading countries
Exhibit 44: Market opportunity
Exhibit 45: Some of the health problems associated with the use of ART
Exhibit 46: Pipeline molecules for treatment of female infertility: Overview
Exhibit 47: Impact of drivers and challenges
Exhibit 48: Cost comparison of follitropin alfa
Exhibit 49: Vendor landscape
Exhibit 50: Landscape disruption
Exhibit 51: Vendors covered
Exhibit 52: Vendor classification
Exhibit 53: Market positioning of vendors
Exhibit 54: Allergan Plc - Vendor overview
Exhibit 55: Allergan Plc - Product segments
Exhibit 56: Allergan Plc - Organizational developments
Exhibit 57: Allergan Plc - Geographic focus
Exhibit 58: Allergan Plc - Segment focus
Exhibit 59: Allergan Plc - Key offerings
Exhibit 60: Allergan Plc - Key customers
Exhibit 61: Ferring BV - Vendor overview
Exhibit 62: Ferring BV - Product segments
Exhibit 63: Ferring BV - Organizational developments
Exhibit 64: Ferring BV - Key offerings
Exhibit 65: Ferring BV - Key customers
Exhibit 66: Merck KGaA - Vendor overview
Exhibit 67: Merck KGaA - Business segments
Exhibit 68: Merck KGaA - Organizational developments
Exhibit 69: Merck KGaA - Geographic focus
Exhibit 70: Merck KGaA - Segment focus
Exhibit 71: Merck KGaA - Key offerings
Exhibit 72: Merck KGaA - Key customers
Exhibit 73: Novartis AG - Vendor overview
Exhibit 74: Novartis AG - Business segments
Exhibit 75: Novartis AG - Organizational developments
Exhibit 76: Novartis AG - Geographic focus
Exhibit 77: Novartis AG - Segment focus
Exhibit 78: Novartis AG - Key offerings
Exhibit 79: Novartis AG - Key customers
Exhibit 80: Sanofi - Vendor overview
Exhibit 81: Sanofi - Business segments
Exhibit 82: Sanofi - Organizational developments
Exhibit 83: Sanofi - Geographic focus
Exhibit 84: Sanofi - Segment focus
Exhibit 85: Sanofi - Key offerings
Exhibit 86: Sanofi - Key customers
Exhibit 87: Validation techniques employed for market sizing
Exhibit 88: Definition of market positioning of vendors
    Note: Product cover images may vary from those shown
    3 of 4

    Loading
    LOADING...

    4 of 4

    FEATURED COMPANIES

    • Allergan Plc
    • Ferring BV
    • Merck KGaA
    • Novartis AG
    • Sanofi.
    • MORE
    The following companies are recognised as the key players in the global female infertility drugs market: Allergan Plc, Ferring BV, Merck KGaA, Novartis AG, and Sanofi.

    Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the introduction of biosimilars”.

    According to the report, one of the major drivers for this market is the adverse outcomes and high cost of non-therapeutics.

    Further, the report states that one of the major factors hindering the growth of this market is the availability of alternative treatment options.

    The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
    Note: Product cover images may vary from those shown
    5 of 4
    • Allergan Plc
    • Ferring BV
    • Merck KGaA
    • Novartis AG
    • Sanofi.
    Note: Product cover images may vary from those shown
    Adroll
    adroll